Kenya to begin routine malaria vaccination program | UK to lead joint research on infectious diseases | Release of sterile biotech mosquitoes proposed for Fla. Keys
September 13, 2019
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP ⋅   FORWARD
ADVERTISEMENT
Top Story
Kenya to begin routine malaria vaccination program
Kenya will begin rolling out a routine malaria immunization for children younger than 2 in eight of its 47 counties. Pilot immunization programs have also been started in Ghana and Malawi.
Reuters (9/13),  The Washington Post (tiered subscription model)/The Associated Press (9/13) 
LinkedIn Twitter Facebook Email
Science & Health
UK to lead joint research on infectious diseases
The UK has partnered with US, Israeli and Chinese experts to conduct research on infectious diseases' evolution and transmission and will donate $10.2 million for the joint research project. The project will be led by the UK Research and Innovation's Biotechnology and Biological Sciences Research Council and will look at interactions between infectious diseases and humans, wildlife and domesticated plants and animals.
The Jerusalem Post (free registration) (9/11) 
LinkedIn Twitter Facebook Email
Release of sterile biotech mosquitoes proposed for Fla. Keys
Florida received a proposal from British firm Oxitec to test its biotech Aedes aegypti mosquitoes, a breed that normally transmits deadly diseases such as dengue and Zika, by releasing them in the Florida Keys to propagate with local mosquitoes. Oxitec's biotech mosquitoes are sterile and have been successfully tested in Jacobina, Brazil.
WUSF-FM (Tampa, Fla.) (9/12) 
LinkedIn Twitter Facebook Email
Industry News & Practice
BioNTech's planned Nasdaq IPO valued at nearly $100M
BioNTech of Germany has submitted documents for its planned Nasdaq initial public offering and expects to raise almost $100 million, an amount much lower than analysts estimated. The funds will support future preclinical and clinical programs for cancer indications, which include chimeric antigen receptor T-cell therapies, messenger RNA drugs, T-cell receptors and others, as well as the expansion of its laboratories and manufacturing plants.
Labiotech (Germany) (9/12) 
LinkedIn Twitter Facebook Email
Jiangsu Hansoh, Atomwise enter drug discovery deal worth up to $1.5B
The Jiangsu Hansoh Pharmaceutical Group and Atomwise have partnered to design and discover possible treatments for up to 11 unnamed target proteins for oncologic and other therapeutic areas, a deal valued up to $1.5 billion. Atomwise uses artificial intelligence technology to help determine the binding capability of small molecules to a target protein.
Genetic Engineering & Biotechnology News (9/12) 
LinkedIn Twitter Facebook Email
Government & Regulatory
EU OKs LumaCyte's Radiance single-cell analysis platform
European regulators have granted CE mark approval to LumaCyte's Radiance single-cell analysis instrument. The device uses laser force cytology technology to measure optical and fluidic forces within a microfluidic channel to analyze each cell's intrinsic cellular properties.
GenomeWeb Daily News (free registration) (9/12) 
LinkedIn Twitter Facebook Email
Association News
AABB to host eCast on platelet contamination
AABB will host an eCast, "HOT TOPIC: Acinetobacter Contamination in Apheresis Platelets -- A Review of Recent Cases" on Tuesday, Sept. 24, at 2 p.m. Eastern Time. In this program, speakers will review four cases of septic transfusion reactions from apheresis platelets contaminated with Acinetobacter calcoaceticus-baumanni (and also Staphylococcus saprophyticus) which were recently reported in Morbidity and Mortality Weekly Report. A description of each case, including the patient's clinical course and investigation performed, will be presented by one of the Blood Center physicians involved in the investigation. A speaker from the Centers for Disease Control and Prevention (CDC) will also review the role the CDC played in the investigation including whole genome sequencing performed on the implicated organisms.
LinkedIn Twitter Facebook Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
  
  
Ditch the dream and be a doer, not a dreamer.
Shonda Rhimes,
television producer, writer
LinkedIn Twitter Facebook Email
  
  
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information